SEC Form 3 FORM 3

UNITED STATES SECURITIES AND EXCHANGE

COMMISSION

Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL

3235-OMB Number: 0104

Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* 2. Date of Ever Powl Brian T. (Month/Day/Ye 08/14/2023		tatement /Year)	3. Issuer Name and Ticker or Trading Symbol Kura Oncology, Inc. [KURA]						
(Last) (First) (Middle) KURA ONCOLOGY, INC. C/O 12730 HIGH BLUFF DRIVE, SUITE 400			4. Relationship of Reporting Issuer (Check all applicable) Director X Officer (give title below)		10% Owner Other (specify below)		 5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting 		
(Street) SAN DIEGO (City) (State) (Zip)			Cr	nief Commercia	al Office	r	A Person	by More than One	
	 hle I - Non	-Derivativ		ities Benefic	ially Or	wned			
1. Title of Security (Instr. 4)			2. Amount o	Securities Beneficially Owned mount of Securities 3. Ownership eficially Owned (Instr. Form: Direct (D) or Indirect (I) (Instr. 5)		ership 4. I Direct Ow Indirect	4. Nature of Indirect Beneficial Ownership (Instr. 5)		
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)									
1. Title of Derivative Security (Instr. 4) 2. Date Exercise Expiration Date (Month/Day/Yee)		ate	3. Title and Amount of Se Underlying Derivative Sec (Instr. 4)		curity Convers		Form:	Ownership (Instr.	
Explanation of Responses:	Date Exercisable	Expiration Date	n c		Amount or Number of Shares	Price of Derivative Security	Direct (D) or Indirect (I) (Instr. 5)	5)	

Remarks:

No securities are beneficially owned.

No securities are beneficially owned.

Teresa Bair, Attorney-in-	
fact for Brian Powl	

08/16/2023

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

LIMITED POWER OF ATTORNEY FOR SECTION 16 REPORTING OBLIGATIONS Know all by these presents, that the undersigned's hereby makes, constitutes and appoints Teresa Bair, J.D. and Thomas Doyle of Kura Oncology, Inc. and Charles Bair of Cooley LLP as the undersigned's true and lawful attorney-in-fact, with full power and authority as hereinafter described on behalf of and in the name, place and stead of the undersigned to: prepare, execute, acknowledge, deliver and file Forms 3, 4, and 5 (including (1)any amendments thereto) with respect to the securities of Kura Oncology, Inc., a Delaware corporation (the "Company"), with the United States Securities and Exchange Commission, any national securities exchanges and the Company, as considered necessary or advisable under Section 16(a) of the Securities Exchange Act of 1934 and the rules and regulations promulgated thereunder, as amended from time to time (the "Exchange Act"); seek or obtain, as the undersigned's representative and on the undersigned's (2) behalf, information on transactions in the Company's securities from any third party, including brokers, employee benefit plan administrators and trustees, and the undersigned hereby authorizes any such person to release any such information to the undersigned and approves and ratifies any such release of information; and perform any and all other acts which in the discretion of such (3)attorney-in-fact are necessary or desirable for and on behalf of the undersigned in connection with the foregoing. The undersigned acknowledges that: this Power of Attorney authorizes, but does not require, such (1)attorney-in-fact to act in their discretion on information provided to such attorney-in-fact without independent verification of such information; any documents prepared and/or executed by such attorney-in-fact on behalf of (2) the undersigned pursuant to this Power of Attorney will be in such form and will contain such information and disclosure as such attorney-in-fact, in his or her discretion, deems necessary or desirable; neither the Company nor such attorney-in-fact assumes (i) any liability for (3)the undersigned's responsibility to comply with the requirement of the Exchange Act, (ii) any liability of the undersigned for any failure to comply with such requirements, or (iii) any obligation or liability of the undersigned for profit disgorgement under Section 16(b) of the Exchange Act; and this Power of Attorney does not relieve the undersigned from responsibility (4)for compliance with the undersigned's obligations under the Exchange Act, including without limitation the reporting requirements under Section 16 of the Exchange Act. The undersigned hereby gives and grants the foregoing attorney-in-fact full power and authority to do and perform all and every act and thing whatsoever requisite, necessary or appropriate to be done in and about the foregoing matters as fully to all intents and purposes as the undersigned might or could do if present, hereby ratifying all that such attorney-in-fact of, for and on

behalf of the undersigned, shall lawfully do or cause to be done by virtue of this Limited Power of Attorney. This Power of Attorney shall remain in full force and effect until revoked by

the undersigned in a signed writing delivered to such attorney-in-fact. IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 19th day of July, 2023.

/s/ Brian Powl

Brian Powl